JP2013536240A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536240A5
JP2013536240A5 JP2013526099A JP2013526099A JP2013536240A5 JP 2013536240 A5 JP2013536240 A5 JP 2013536240A5 JP 2013526099 A JP2013526099 A JP 2013526099A JP 2013526099 A JP2013526099 A JP 2013526099A JP 2013536240 A5 JP2013536240 A5 JP 2013536240A5
Authority
JP
Japan
Prior art keywords
peptide
pharmaceutical composition
composition according
epha2
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013526099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013536240A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/048823 external-priority patent/WO2012027379A2/en
Publication of JP2013536240A publication Critical patent/JP2013536240A/ja
Publication of JP2013536240A5 publication Critical patent/JP2013536240A5/ja
Pending legal-status Critical Current

Links

JP2013526099A 2010-08-24 2011-08-23 インターロイキン−１３受容体α２ペプチド脳がんワクチン Pending JP2013536240A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37658210P 2010-08-24 2010-08-24
US61/376,582 2010-08-24
PCT/US2011/048823 WO2012027379A2 (en) 2010-08-24 2011-08-23 Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016139885A Division JP6511021B2 (ja) 2010-08-24 2016-07-15 インターロイキン−１３受容体α２ペプチド脳がんワクチン

Publications (2)

Publication Number Publication Date
JP2013536240A JP2013536240A (ja) 2013-09-19
JP2013536240A5 true JP2013536240A5 (enExample) 2014-10-02

Family

ID=45724024

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013526099A Pending JP2013536240A (ja) 2010-08-24 2011-08-23 インターロイキン−１３受容体α２ペプチド脳がんワクチン
JP2016139885A Active JP6511021B2 (ja) 2010-08-24 2016-07-15 インターロイキン−１３受容体α２ペプチド脳がんワクチン
JP2019072379A Active JP6931240B2 (ja) 2010-08-24 2019-04-05 インターロイキン−１３受容体α２ペプチド脳がんワクチン
JP2021129288A Active JP7793167B2 (ja) 2010-08-24 2021-08-05 インターロイキン－１３受容体α２ペプチド脳がんワクチン
JP2023146554A Withdrawn JP2023175764A (ja) 2010-08-24 2023-09-08 インターロイキン－１３受容体α２ペプチド脳がんワクチン

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016139885A Active JP6511021B2 (ja) 2010-08-24 2016-07-15 インターロイキン−１３受容体α２ペプチド脳がんワクチン
JP2019072379A Active JP6931240B2 (ja) 2010-08-24 2019-04-05 インターロイキン−１３受容体α２ペプチド脳がんワクチン
JP2021129288A Active JP7793167B2 (ja) 2010-08-24 2021-08-05 インターロイキン－１３受容体α２ペプチド脳がんワクチン
JP2023146554A Withdrawn JP2023175764A (ja) 2010-08-24 2023-09-08 インターロイキン－１３受容体α２ペプチド脳がんワクチン

Country Status (9)

Country Link
US (5) US20120052080A1 (enExample)
EP (3) EP3511013B1 (enExample)
JP (5) JP2013536240A (enExample)
AU (1) AU2011293522B2 (enExample)
CA (2) CA3066981A1 (enExample)
DK (1) DK2608799T3 (enExample)
ES (2) ES2930809T3 (enExample)
MX (1) MX353165B (enExample)
WO (1) WO2012027379A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120052080A1 (en) * 2004-09-21 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US7612162B2 (en) * 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
CA2626238C (en) 2005-10-17 2015-10-06 Memorial Sloan Kettering Cancer Center Wt1 hla class ii-binding peptides and compositions and methods comprising same
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
US8129184B2 (en) 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
PL2328923T3 (pl) * 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
US9187534B2 (en) * 2011-03-11 2015-11-17 Universite De Geneve Multi-epitopic vaccine
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
EP3855184B1 (en) * 2012-03-19 2023-12-27 Stemline Therapeutics Inc. Methods for treating and monitoring the status of cancer
US9662329B2 (en) 2012-03-26 2017-05-30 University of Pittsburgh—of the Commonwealth System of Higher Education Use of survivin antagonists in polyomavirus-related disease
RS62406B1 (sr) * 2012-05-16 2021-10-29 Stemline Therapeutics Inc Vakcine protiv kancera sa ciljanim delovanjem na matične ćelije kancera
RU2015104001A (ru) * 2012-08-07 2016-09-27 Дженентек, Инк. Комбинированная терапия для лечения глиобластомы
WO2014041505A1 (en) 2012-09-13 2014-03-20 Universite De Geneve Cell penetrating peptides
WO2014070663A1 (en) * 2012-10-29 2014-05-08 Anderson David E Compositions and methods for diagnosis and treatment of malignant gliomas
CA2888803A1 (en) * 2012-11-05 2014-05-08 Jooeun Bae Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
KR102045029B1 (ko) * 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
US20140234351A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
PL2970492T3 (pl) * 2013-03-15 2019-10-31 Univ Wake Forest Health Sciences Przeciwciała przeciwko ludzkim i psim il-13ra2
EP2978450B1 (en) 2013-03-27 2018-09-19 ImmunoVaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
EP3008212A4 (en) * 2013-06-10 2017-05-24 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP6740127B2 (ja) * 2013-12-06 2020-08-12 ザ・ブロード・インスティテュート・インコーポレイテッド 新生物ワクチン用製剤
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
CN103768595B (zh) * 2014-01-27 2016-03-02 中国医学科学院医学生物学研究所 唑来膦酸佐剂及含唑来膦酸佐剂的疫苗
JP2017523776A (ja) 2014-07-14 2017-08-24 ジェネンテック， インコーポレイテッド 膠芽腫の診断方法及びその治療用組成物
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
PT3429618T (pt) 2016-03-16 2024-04-02 Amal Therapeutics Sa Combinação de um modulador de ponto de controlo imunitário e um complexo que compreende um péptido de penetração celular, uma carga e um agonistra peptídico de tlr para utilização em medicina
IL265479B (en) 2016-09-21 2022-09-01 Amal Therapeutics Sa A fusion containing a cell-penetrating peptide, a multiple epitope, and a peptide tlr agonist for cancer therapy
CN110049774A (zh) 2016-10-07 2019-07-23 恩特罗姆公司 肿瘤相关抗原表位的小型生物群序列变体
IL302345B2 (en) 2016-10-07 2024-12-01 Enterome S A Immunogenic compounds for cancer therapy
CN110022894B (zh) * 2016-10-07 2024-01-19 恩特罗姆公司 用于癌症疗法的免疫原性化合物
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP7232825B2 (ja) * 2017-10-09 2023-03-03 エンテローム エスエー 腫瘍関連抗原エピトープの微生物叢（ｍｉｃｒｏｂｉｏｔａ）配列変異体
JP2018070629A (ja) * 2017-11-28 2018-05-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． がんの処置におけるサバイビンワクチンの有効性を向上させるための方法
CN107903305B (zh) * 2017-12-25 2020-11-13 陕西慧康生物科技有限责任公司 一种固液联合合成地索莫泰的方法
WO2019197563A2 (en) * 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
DK3773689T5 (da) 2018-04-11 2024-08-19 Enterome S A Antigene peptider til forebyggelse og behandling af kræft
JP7591829B2 (ja) * 2019-08-05 2024-11-29 国立大学法人佐賀大学 中空コラーゲンゲル
DE102019214359A1 (de) * 2019-09-20 2021-03-25 Siemens Healthcare Gmbh Verfahren zu einer adaptiven Ansteuerung eines Magnetresonanzgerätes

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA117152A (en) 1908-12-04 1909-03-09 George A. Stebbins Sulphur burner
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
AU677772B2 (en) 1991-10-07 1997-05-08 Biogen Idec Ma Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA -3 interaction
EP0793501A4 (en) 1994-12-14 2000-05-03 Scripps Research Inst IN VIVO ACTIVATION OF TUMOR SPECIFIC CYTOTOXIC T CELLS
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
CA2439222C (en) 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
AU2002306651B2 (en) 2001-03-02 2007-12-13 Medimmune, Llc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists
WO2002098370A2 (en) 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
FR2838742B1 (fr) 2002-04-23 2004-07-09 Inst Nat Sante Rech Med Epitopes t de l'antigene epha2
WO2004087758A2 (en) * 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
KR20110094361A (ko) 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
ES2456666T3 (es) * 2003-04-18 2014-04-23 Biotech Synergy, Inc. Péptidos antígenos HLA-A2 asociados a un tumor y composiciones
JP2004353820A (ja) 2003-05-30 2004-12-16 Toyota Motor Corp トリポート型等速ジョイント部品およびトリポート型等速ジョイント
WO2005012350A2 (en) 2003-07-30 2005-02-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Epha2 t-cell epitope agonists and uses therefor
IL158140A0 (en) * 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
US20050281783A1 (en) * 2003-10-15 2005-12-22 Kinch Michael S Listeria-based EphA2 vaccines
EP2087904B1 (en) * 2003-11-19 2013-08-28 Survac ApS Therapeutic use of peptides derived from Bcl-XL protein in cancer patients
EP2478913A1 (en) 2003-12-01 2012-07-25 Sloan-Kettering Institute For Cancer Research Synthetic HLA binding peptide analogues and uses thereof
US20050153923A1 (en) 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
EP1732580A4 (en) * 2003-12-24 2008-01-23 Medimmune Inc EPHA2 VACCINES
US20120052080A1 (en) 2004-09-21 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
EP1835027B1 (en) 2004-12-07 2015-02-25 Toray Industries, Inc. Novel cancer antigen peptide and the use thereof
CA2626238C (en) * 2005-10-17 2015-10-06 Memorial Sloan Kettering Cancer Center Wt1 hla class ii-binding peptides and compositions and methods comprising same
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
US8871211B2 (en) * 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
CN101754768B (zh) 2007-07-19 2013-07-10 健康研究股份有限公司 用作癌症疫苗的存活蛋白肽
JP5478260B2 (ja) * 2007-12-05 2014-04-23 株式会社癌免疫研究所 癌ワクチン組成物
RS53782B1 (sr) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
US8728806B2 (en) * 2008-12-06 2014-05-20 The Board Of Regents, The University Of Texas System Methods and compositions related to Th-1 dendritic cells
US20110223187A1 (en) * 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy

Similar Documents

Publication Publication Date Title
Ho et al. Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines?
Li et al. Elastic Nanovaccine Enhances Dendritic Cell‐Mediated Tumor Immunotherapy
Zhang et al. PH-controlled release of antigens using mesoporous silica nanoparticles delivery system for developing a fish oral vaccine
JP2016539946A5 (enExample)
Müller et al. Inflammation, immunity, and vaccine development for Helicobacter pylori
JP2013536157A5 (enExample)
JP2016513638A5 (enExample)
JP2017524682A5 (enExample)
JP2012021028A5 (enExample)
JP2015110588A5 (enExample)
JP2008530245A5 (enExample)
Xiang et al. Promising particle-based vaccines in cancer therapy
JP2012528794A5 (enExample)
JP2019531293A5 (enExample)
JP2012500184A5 (enExample)
Saung et al. Particulate carrier systems as adjuvants for cancer vaccines
JP2011525902A5 (enExample)
Qu et al. A Biomimetic Autophagosomes‐Based Nanovaccine Boosts Anticancer Immunity
Kim et al. Enhancement of immune responses elicited by nanovaccines through a cross-presentation pathway
JP2006502228A5 (enExample)
Rong et al. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine
JP2014139185A5 (enExample)
Zhang et al. Polymer–protein core–shell nanoparticles for enhanced antigen immunogenicity
Zhu et al. Tumor antigen delivered by Salmonella III secretion protein fused with heat shock protein 70 induces protection and eradication against murine melanoma
RU2008142140A (ru) Противотуберкулезная вакцина